A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal ® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

Michael R. Harrison, Noah M. Hahn, Roberto Pili, William K. Oh, Hans Hammers, Christopher Sweeney, Kyung Mann Kim, Scott Perlman, Jamie Arnott, Carolyn Sidor, George Wilding, Glenn Liu

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal ® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)'. Together they form a unique fingerprint.

Medicine & Life Sciences